The partnership aims to bring a fully integrated, on-body delivery system platform for subcutaneous administration to market.
Stevanato Group said the device will be semi-reusable and provide micro-precision basal doses and full-content bolus injections. The company intends for the flexible, customizable platform to administer a wide range of therapies.
Get the full story at our sister site, Drug Delivery Business News.
Thermo Fisher Scientific (NYSE: TMO) announced that its board of directors has authorized the repurchase of $4 billion of shares of its common stock.
The repurchases, announced Nov. 10, could take place in the open market or in negotiated transactions. The board’s authorization has no expiration date.
During its Q3 earnings call last month, Thermo Fisher officials announced they were increasing the company’s full-year revenue guidance by $650 million to $43.8 billion, which would represent 12% growth. In addition, they upped the life science research and diagnostic tech company’s adjusted EPS guidance by 8¢ to $23.01 per share.
For the first nine months of 2022, the company earned nearly $5.4 billion, or $13.62 per share, off $33.5 billion in revenue. The results represented a bottom-line decline of 11% on sales growth of 17%.
Still, the TMO shares are down from a peak over the summer — a performance that mirrors the overall mark…
Thermo Fisher Scientific (NYSE:TMO) announced today that it entered into a definitive agreement to acquire The Binding Site Group.
The Binding Site develops specialty diagnostic assays and instruments. It designs its technology to improve the diagnosis and management of blood cancers and immune system disorders. The Binding Site’s Freelite offering aids in multiple myeloma diagnosis and monitoring.
Waltham, Massachusetts-based Thermo Fisher agreed to acquire The Binding Site from a shareholder group led by European private equity firm Nordic Capital. It values the all-cash transaction at $2.6 billion (£2.25 billion).
Birmingham, U.K.–based The Binding Site has a workforce of more than 1,100 around the globe. It remains on track to deliver more than $220 million in revenue in 2022.
‘An exciting addition’“This transaction perfectly aligns with our mission and is an exciting addition to our existing specialty diagnostic offerings. …
That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance. In addition, rating sites like Glassdoor also indicate CEOs’ popularity.
Here, we parsed a range of metrics, including CEOs’ approval ratings, their ability to navigate the pandemic and their firms’ stock performance over time, to identify ten leading pharma executives.
Get the full story from our sister site, Drug Discovery & Development.
Waltham, Massachusetts-based Thermo Fisher designed its Renvo rapid in-air pathogen PCR test for detecting the virus on air samples collected through the company’s Thermo Scientific AerosolSense Sampler.
According to a news release, the company designed the test for environmental surveillance only, rather than diagnostic purposes, in communal locations like schools, businesses, healthcare facilities, government buildings nad other public areas. It offers fast, accurate detection of SARS-CoV-2 (the virus causing COVID-19) pathogens through indoor air sampling without the need for specialized training or sending samples to a lab for analysis.
Thermo Fisher’s system uses proprietary Oscar PCR technology to shorten thermocycling times and produce results in just 30 minutes, improving on the four to 24…
Thermo Fisher Scientific (NYSE:TMO) today posted fourth-quarter results that beat the overall consensus on Wall Street.
The Waltham, Massachusetts–based laboratory supply company reported profits of $1.7 billion, or $4.17 per share, on sales of $10.7 billion for the three months ended Dec. 31, 2021, for a bottom-line loss of -33.6% on sales growth of 1.42% compared with Q4 2020.
Adjusted to exclude one-time items, earnings per share were $6.54, $1.27 ahead of The Street, where analysts were looking for sales of $9.29 billion.
“We had an outstanding 2021, as we continued to execute our proven growth strategy, powered by our PPI Business System, and operated with speed at scale to help our customers and governments around the world advance their important work,” president and CEO Marc Casper said in a news release. “We exceeded the goals we set out to accomplish in 2021 and delivered for all of our stakeholders.”
Shares in TM…
Oncocyte (NSDQ:OCX) announced yesterday that it entered into a development and co-marketing agreement with Thermo Fisher Scientific (NYSE:TMO).
The development and co-marketing agreement covers two distributed in vitro diagnostic (IVD) assays on Thermo Fisher’s Ion Torrent Genexus system and grants Oncocyte the rights to develop future companion diagnostics on the Genexus system.
Under the collaboration terms, Oncocyte will clinically validate Thermo Fisher’s existing Oncomine Comprehensive Assay Plus on the Genexus system to accelerate it toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic, according to a news release.
The 500-gene assay could initially provide physicians with information about tumors in accordance with established clinical evidence, Oncocyte said.
Oncocyte will also develop its 27-gene expression DetermaIO test as a distributed kit on Thermo Fisher’s Genexus platform…
Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its acquisition of PeproTech for approximately $1.85 billion.
Cranbury, New Jersey-based PeproTech develops recombinant proteins, including cytokines and growth factors, for use in the development and manufacturing of cell and gene therapies, as well as in other broader cell culture applications.
Get the full story at our sister site, Drug Discovery & Development.
Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its previously announced $17.4 billion acquisition of PPD.
Waltham, Massachusetts-based Thermo Fisher announced in April that it would acquire the company that provides clinical research services to the biopharma and biotech industry. PPD ceased trading on the Nasdaq prior to opening today and will become part of Thermo Fisher’s laboratory products and services segment.
Get the full story at our sister site, Drug Discovery & Development.
Several medtech, healthcare and life sciences companies, including big names like Abbott (NYSE:ABT), 3M (NYSE:MMM) and Baxter (NYSE:BAX), are among the 500 “most responsible,” according to Newsweek.
The outlet published its “America’s Most Responsible Companies 2022” list, marking the third installment of the compilation (in partnership with Statista), this time expanded to include 500 of the largest public corporations around. Companies were judged with an overall score out of 100 that combined environmental, social and corporate governance performance assessments.
Baxter, 3M, Abbott and BD (NYSE:BDX) were among the highest-ranking big-name medical device makers. Cancer diagnostic company Illumina was the highest-ranking company under the healthcare and life sciences umbrella, sitting in second behind HP.
In sixth sat Baxter, registering an overall score of 89.5 points, with its highest performance coming in environmental i…
Discovered last week in South Africa, the new variant has enough mutations that it has raised concerns worldwide — even though it is still unknown for sure whether the mutations cause greater transmissibility or vaccine evasion. The United States is among the countries restricting travel from southern Africa for the time being, and the CDC is advising all adults to get a booster shot.
Get the full story on our sister site Medical Design & Outsourcing.
Thermo Fisher Scientific (NYSE:TMO) said today that its TaqPath diagnostic kit can detect the emerging Omicron variant of COVID-19.
Waltham, Massachusetts-based Thermo Fisher’s polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit and TaqPath COVID-19 CE-IVD RT-PCR Kit, which test for the presence of SARS-CoV-2 (the virus causing COVID-19), offer accurate results for samples with the latest variant of the virus, B.1.1.529 (“Omicron”).
Omicron was recently designated as a “variant of concern” by the World Health Organization (WHO) as it contains more than 30 mutations in the spike protein alone, posing a potential problem of increased transmission when compared to other variants. The emergence of Omicron has led to new travel restrictions and increased research to assess its impact on vaccines and diagnostics.
TaqPath assays detect SARS-CoV-2 infections by identifying the presence of three gene targets from the orf1a/b, …